Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07553286 Cetylpyridinium Chloride Hydrate Periodontal Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07553286 Cetylpyridinium Chloride Hydrate Periodontal Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07553286 clinical trial report covering Cetylpyridinium Chloride Hydrate, Phase 3, endpoints, sponsor, geography, readout timing and development white spac
Read →
CTR20261336 Indacaterol Acetate/Mometasone Furoate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261336 Indacaterol Acetate/Mometasone Furoate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261336 clinical trial report covering Indacaterol Acetate/Mometasone Furoate, Phase 3, endpoints, sponsor, geography, readout timing and development whit
Read →
ChiCTR2600123580 Dexamethasone Sodium Phosphate Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600123580 Dexamethasone Sodium Phosphate Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
ChiCTR2600123580 clinical trial report covering Dexamethasone Sodium Phosphate, Phase 3, endpoints, sponsor, geography, readout timing and development white s
Read →
ChiCTR2600123594 Adebrelimab Non-squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600123594 Adebrelimab Non-squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
ChiCTR2600123594 clinical trial report covering Adebrelimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07554495 Filgotinib Maleate Polyarticular Juvenile Idiopathic Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07554495 Filgotinib Maleate Polyarticular Juvenile Idiopathic Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07554495 clinical trial report covering Filgotinib Maleate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07553351 Human Growth Hormone (Shandong Kexing Bioproducts) Growth Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07553351 Human Growth Hormone (Shandong Kexing Bioproducts) Growth Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07553351 clinical trial report covering Human Growth Hormone (Shandong Kexing Bioproducts), Phase 3, endpoints, sponsor, geography, readout timing and deve
Read →
NCT07554339 Durvalumab KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07554339 Durvalumab KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07554339 clinical trial report covering Durvalumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07556848 Bulumtatug fuvedotin Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07556848 Bulumtatug fuvedotin Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07556848 clinical trial report covering Bulumtatug fuvedotin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07556731 Ferrous Succinate Anemia, Iron-Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07556731 Ferrous Succinate Anemia, Iron-Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07556731 clinical trial report covering Ferrous Succinate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07555938 Cevostamab Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07555938 Cevostamab Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07555938 clinical trial report covering Cevostamab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07557420 Ravulizumab-CWVZ Neuromyelitis Optica Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07557420 Ravulizumab-CWVZ Neuromyelitis Optica Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07557420 clinical trial report covering Ravulizumab-CWVZ, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07559877 Chlorhexidine gluconate Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07559877 Chlorhexidine gluconate Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07559877 clinical trial report covering Chlorhexidine gluconate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →